Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC
Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.
You may also be interested in...
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.
Lilly's $8bn acquisition of genetics-based cancer specialist Loxo Oncology didn't involve any other bidders and was finalized in just days over the holidays as Lilly sought to make a news splash at the J.P. Morgan Healthcare conference, according to an SEC filing.